GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Other Assets for Insurance Companies

Biomarin Pharmaceutical (FRA:BM8) Other Assets for Insurance Companies


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Other Assets for Insurance Companies?

Other Assets for Insurance Companies only applies to insurance companies.


Biomarin Pharmaceutical (FRA:BM8) Business Description

Industry
Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.